MarketNancy T. Chang
Company Profile

Nancy T. Chang

Chang Tang Chang, also known by her English name Nancy Chang, is a Taiwanese biochemist. She co-founded the biopharmaceutical company Tanox in 1986. She also developed the asthma drug Xolair. In June 2003, the U.S. Food and Drug Administration (FDA) approved Xolair, the first biotech product cleared for treating those with asthma related to allergies. Tanox was also active in the development of TNX-355, an antibody for the treatment of HIV/AIDS. In 2007, Tanox was sold to Genentech for $919 million.

Early life and education
Chang was born in Taiwan in 1950. Her mother was a surgeon and her father was a civil engineer; they were wealthy waishengren who migrated to Taiwan after their marriage during the Great Retreat. Chang studied chemistry and physics at Taipei First Girls' High School in Taipei. After graduation, she attended National Tsing Hua University, where one of her undergraduate teachers was Nobel Prize laureate Yuan T. Lee and one of her classmates was scientist Tse Wen Chang. Chang married Tse a few days before traveling to the United States, where both had received scholarships for graduate school: Chang at Brown University and Tse Wen at Harvard University. Chang also completed additional undergraduate studies at Brown University. On the plane ride to the United States, Chang read James Watson’s book on the discovery of the double helix. This sparked her interest in biology, which she had not previously studied. Chang subsequently changed her academic focus to biology and transferred to Harvard University to study medical sciences at Harvard Medical School. The Changs were among the first international students at the Harvard Division of Medical Sciences, but Chang had to overcome an initially poor comprehension of English. She earned her Ph.D. in biological chemistry from Harvard Medical School in 1981. ==Work==
Work
Her interest in interferon led her to approach Sidney Pestka at Roche Pharmaceutical Company Chang is an angel investor in health-care entrepreneurships and performs philanthropic work in community health-education projects. As part of Project Hope's China programs, she has had the responsibility of assessing annual progress in programs at Wuhan University School of Medicine, Shanghai Children's Medical Center, and educational programs and treatments for diabetes and HIV/AIDS. As of 2009, Chang was the chairman and managing director of OrbiMed's Caduceus Asia partner fund and a member of Orbimed Advisors, the largest investment firm focused entirely on the healthcare sector. As of 2013, Chang Chang was president of Apex Enterprises. ==Honors and awards==
Honors and awards
During her career, Chang has received numerous academic, national and international awards for her leadership and contributions to the biopharmaceutical industry. Chang Chang was inducted into the Texas Science Hall of Fame in 2001, for exemplary achievement in science. In 2005, she was named a Most Respected Woman in Biotechnology (MedAd News, 2005), and also received the Global Business Achievement Hall of Fame Governor's Award from the Global Federation of Chinese Business Women in the Southern U.S. In 2008 Chang was named to the Forbes Twenty-Five Notable Chinese Americans list. In 2012, she became the first woman to receive the 14th annual Biotechnology Heritage Award, conferred by the Biotechnology Industry Organization (BIO) and the Chemical Heritage Foundation. She is the recipient of several additional awards, such as the Association of Women in Computing: Top 20 Houston Women in Technology and Houston Entrepreneur of the Year. ==References==
tickerdossier.comtickerdossier.substack.com